Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Can-Fite BioPharma Ltd. (CANF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Can-Fite files an annual report on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical programs, financial results, capital structure, and corporate actions. These filings are sourced in real time from the SEC’s EDGAR system and are organized for convenient review.
In its Form 6-K reports, Can-Fite often furnishes press releases covering developments such as clinical trial enrollment updates for Namodenoson in hepatocellular carcinoma, MASH, and pancreatic cancer; Phase III progress for Piclidenoson in psoriasis; and new data from compassionate use programs in advanced liver disease. Filings also document regulatory designations like Orphan Drug and Fast Track status, patent grants and notices of allowance, and information about veterinary and human licensing agreements.
CANF’s SEC reports additionally address corporate and financing matters, including public offerings, warrant amendments, reverse stock splits, ADS ratio changes, and shareholder meeting outcomes. Financial statements presented under U.S. GAAP outline revenues from licensing and distribution agreements, research and development expenses for its A3 adenosine receptor-targeted pipeline, and general and administrative costs.
On this page, users can review individual filings and use AI-powered summaries to quickly understand the key points of lengthy documents such as the Form 20-F and detailed Form 6-K exhibits. The platform also makes it easier to track how specific clinical, regulatory, and capital markets events are reflected across multiple filings over time.
Can-Fite BioPharma Ltd. director and Chief Scientific Officer Pnina Fishman reported her initial holdings on a Form 3. She directly holds several option grants to purchase Ordinary Shares with exercise prices ranging from USD 17.39 to USD 2,264.01, plus 88 Ordinary Shares. Some options are fully vested and exercisable, while others continue vesting in quarterly installments through dates extending to June 30, 2029, subject to her continued service.
Can-Fite BioPharma Ltd. executive Motti Farbstein, who serves as CEO, CFO and COO, files an initial Form 3 disclosing his holdings of stock options on the company’s ordinary shares. The filing lists several direct option grants with exercise prices ranging from $17.47 to $2,439.02 per share and expirations from 2027 through 2035. Some grants are fully vested and exercisable, while others continue to vest in scheduled quarterly installments through 2029, subject to his continued service. The options were issued under Can-Fite’s 2003, 2013 and 2023 share option plans, and for Israeli tax purposes are registered in the name of a trustee.
Can-Fite BioPharma Ltd. reports that the Israeli Patent Office has allowed its patent application covering the use of A3 adenosine receptor agonists, including its lead drug Namodenoson, to induce fat loss and treat obesity and related metabolic disorders. This strengthens the company’s global intellectual property around Namodenoson’s anti-obesity activity, following similar patent advances in the US, Canada and Australia. The company highlights preclinical and clinical data suggesting Namodenoson can reduce fat accumulation and improve metabolic profiles, offering a differentiated mechanism from current GLP-1 obesity drugs. The global obesity treatment market is projected to reach $60.5 billion by 2030, growing at a compound annual rate of about 22%.
Can-Fite BioPharma Ltd. reported that a Special General Meeting of Shareholders held on March 10, 2026 approved all three proposals presented to shareholders. These proposals were previously outlined in the company’s Notice and Proxy Statement dated January 27, 2026, which had been furnished on Form 6-K.
Can-Fite Biopharma Ltd. is updating its Form F-1 registration (Registration No. 333-288890) via a prospectus supplement dated March 5, 2026 to cover up to 1,250,000 American Depositary Shares (representing 2,500,000 ordinary shares) and related warrants and pre-funded warrants.
The supplement incorporates a Form 6-K describing an inducement arrangement: a holder agreed to exercise 795,869 Existing Warrants for cash at a reduced price of $5.00 per ADS, yielding approximately $4.0 million gross proceeds, and the Company will issue New Warrants to purchase 1,591,738 ADSs at $5.00. The Company engaged H.C. Wainwright as placement agent with a 7.0% cash fee, a 1.0% management fee and Placement Agent Warrants to purchase 55,711 ADSs at an exercise price of $6.25. The closing was expected on or about March 5, 2026, and the Company agreed to file a resale registration statement and use commercially reasonable efforts to have it declared effective within 90 days.
Can-Fite BioPharma Ltd. entered a definitive inducement agreement leading to the immediate cash exercise of warrants to purchase 795,869 ADSs at a reduced exercise price of $5.00 per ADS, generating expected gross proceeds of approximately $4.0 million before fees.
In return, the investor will receive new unregistered warrants to purchase up to 1,591,738 ADSs at $5.00 per ADS, exercisable until two years after the effectiveness of a resale registration statement. H.C. Wainwright & Co. will receive fees, expense reimbursements and warrants for 55,711 ADSs. Can-Fite plans to use net proceeds for research and development, clinical trials, and general corporate purposes.
Can-Fite BioPharma Ltd. reported that its drug candidate namodenoson successfully met the primary endpoint of safety in a Phase 2a study for advanced pancreatic ductal adenocarcinoma. In this open-label trial, 20 heavily pretreated patients received namodenoson, and the treatment was described as very well tolerated with no new safety signals.
The safety profile in pancreatic cancer was consistent with prior experience in other oncological indications. Secondary endpoints include overall survival and progression-free survival; survival follow-up is ongoing, with about one-third of patients alive at the data cut-off. Namodenoson, a selective A3 adenosine receptor agonist, has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also being studied in liver cancer and MASH.
Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders on March 3, 2026, but it was adjourned for one week because there were not enough shareholders present to form a quorum. The Meeting is now scheduled to reconvene on March 10, 2026 at 3:00 p.m., Israel time.
The reconvened Meeting will take place at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. This update simply informs shareholders of the new date, time and place so they can attend and participate in the Meeting.
Can-Fite BioPharma filed a 6-K describing a new peer-reviewed publication showing an anti-obesity effect of its lead drug candidate, namodenoson. In cell and high-fat diet mouse models, namodenoson reduced adipocyte proliferation, lipid accumulation, and weight gain, while modulating metabolic and inflammatory pathways such as adiponectin, PI3K, NF-κB, Akt, and Wnt/β-catenin.
The findings align with earlier Phase IIa data in MASH patients, where three months of treatment was associated with reduced liver fat and body weight, and support further evaluation of namodenoson as a potential oral obesity treatment. Namodenoson is already in Phase III for advanced liver cancer and Phase IIb for MASH, and the company notes obesity as a rapidly growing market projected to reach $60.5 billion by 2030.
Can-Fite BioPharma Ltd. reports that the Canadian Patent Office has issued a notice of allowance for a patent covering its oral drug Namodenoson as an anti-obesity therapy. The patent protects the use of this A3 adenosine receptor agonist to reduce fat mass and body weight in Canada.
The patent stems from data showing Namodenoson increased adiponectin, a hormone that regulates fat production, reduced body weight in an obesity animal model, and produced a 2.3% weight loss over three months in a MASH Phase IIa study. Can-Fite already holds similar Namodenoson obesity patents in the United States and Australia.
Namodenoson is also in Phase III for advanced liver cancer, Phase IIb for MASH, and Phase IIa for pancreatic cancer, and has shown an excellent oral safety profile across multiple clinical studies. Can-Fite highlights that expanding intellectual property into metabolic indications like fat loss may support future development and partnering, within a global obesity treatment market projected to reach $60.5 billion by 2030 with a ~22% CAGR.